Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Lay Description
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
Category
- Cancers and Other Neoplasms
- Child Health
- Multiple Sites
- IRB Number
- 20170390HU
- NCT Number
- NCT02932280
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Between 3 Years and 21 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Principal Investigator
Anne-Marie Langevin